Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer

Journal of Pathology

Volumn 222, Issue 1, 2010, Pages 89-98

  Castillo, Sandra D ^a   Angulo, Barbara ^b,d   Suarez Gauthier, Ana ^b,d   Melchor, Lorenzo ^b   Medina, Pedro P ^b   Sanchez Verde, Lydia ^b   Torres Lanzas, Juan ^c   Pita, Guillermo ^b   Benitez, Javier ^b   Sanchez Cespedes, Montse ^a,b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b Structural Biology and Biocomputing Programme   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^d Hospital Universitario   (Spain)

Author keywords

CTNND1; Lung cancer; Oncogene; p120ctn; TFDP1

Indexed keywords

PROTEIN; PROTEIN CTNND1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR DP1; UNCLASSIFIED DRUG;

AMPLICON; ARTICLE; CELL VIABILITY; CHROMOSOME 11Q; CHROMOSOME 11Q12; CHROMOSOME 13Q; CHROMOSOME 13Q34; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

CARCINOMA, NON-SMALL-CELL LUNG; CATENINS; CELL SURVIVAL; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 13; CLUSTER ANALYSIS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR DP1; TUMOR CELLS, CULTURED;

EID: 77955485964     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2732     Document Type: Article

References (35)

1. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112: 4808-4817.
2. Kitamura Y. Gastrointestinal stromal tumors: past, present, and future. J Gastroenterol 2008; 43: 499-508.
3. Paez JG, Janne PA, Lee JC, et al . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500. (Pubitemid 38720929)
4. Lynch TJ, Bell DW, Sordella R, et al . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 20: 2129-2139. (Pubitemid 38637993)
5. Rosell R, Moran T, Queralt C, et al . Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
6. Pao W, Miller V, Zakowski M, et al . EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
7. Conde E, Angulo B, Tang M, et al . Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signalling. Clin Cancer Res 2006; 12: 710-717. (Pubitemid 43259849)
8. Mitsudomi T, Kosaka T, Endoh H, et al . Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513-2520.
9. Thomas RK, Baker AC, Debiasi RM, et al . High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39: 347-351.
10. McDermott U, Sharma SV, Dowell L, et al . Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 2007; 104: 19936-19941.
11. Angulo B, Suarez-Gauthier A, Lopez-Rios F, et al . Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 2008; 214: 347-356. (Pubitemid 351212390)
12. Blanco R, Iwakawa R, Tang M, et al . A gene-alteration profile of human lung cancer cell lines. Hum Mutat 2009; 30: 1199-1206.
13. McDermott U, Ames RY, Iafrate AJ, et al . Ligand-dependent platelet-derived growth factor receptor (PDGFR)-α activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors Cancer Res 2009; 69: 3937-3946.
14. Greshock J, Naylor TL, Margolin A, et al . 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. Genome Res 2004; 14: 179-187. (Pubitemid 38088539)
15. Melchor L, Honrado E, García MJ, et al . Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene 2008; 27: 3165-3175. (Pubitemid 351693170)
16. Liu Y, Xu HT, Dai SD, et al . Reduction of p120(ctn) isoforms 1 and 3 is significantly associated with metastatic progression of human lung cancer. APMIS 2007; 115: 848-856. (Pubitemid 47030109)
17. Bass AJ, Watanabe H, Mermel CH, et al . SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009; 41: 1238-1242.
18. Choi YW, Choi JS, Zheng LT, et al . Comparative genomic hybridization array analysis and real time PCR reveals genomic alterations in squamous cell carcinomas of the lung. Lung Cancer 2007; 55: 43-51.
19. Weir BA, Woo MS, Getz G, et al . Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450: 893-898.
20. Medina PP, Castillo SD, Blanco S, et al . The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer. Hum Mol Genet 2009; 18: 1343-1352.
21. Varis A, Wolf M, Monni O, et al . Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res 2002; 62: 2625-2629. (Pubitemid 34462744)
22. Arriola E, Marchio C, Tan DS, et al . Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008; 88: 491-503. (Pubitemid 351581454)
23. Perez-Moreno M, Fuchs E. Catenins: keeping cells from getting their signals crossed. Dev Cell 2006; 11: 601-612.
24. Daniel JM. Dancing in and out of the nucleus: p120(ctn) and the transcription factor Kaiso. Biochim Biophys Acta 2007; 1773: 59-68.
25. Paredes J, Correia AL, Ribeiro AS, et al . Breast carcinomas that co-express E- and P-cadherin are associated with p120-catenin cytoplasmic localisation and poor patient survival. J Clin Pathol 2008; 61: 856-862.
26. Liu Y, Wang Y, Zhang Y, et al . Abnormal expression of p120-catenin, E-cadherin, and small GTPases is significantly associated with malignant phenotype of human lung cancer. Lung Cancer 2009; 63: 375-382.
27. Perez-Moreno M, Song W, Pasolli HA, et al . Loss of p120 catenin and links to mitotic alterations, inflammation, and skin cancer. Proc Natl Acad Sci USA 2008; 105: 15399-16404.
28. Shinomiya T, Mori T, Ariyama Y, et al . Comparative genomic hybridization of squamous cell carcinoma of the esophagus: the possible involvement of the DPI gene in the 13q34 amplicon. Genes Chrom Cancer 1999; 24: 337-344.
29. Yasui K, Arii S, Zhao C, et al . TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 2002; 35: 1476-1484. (Pubitemid 34966902)
30. Abba MC, Fabris VT, Hu Y, et al . Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34. Cancer Res 2007; 67: 4104-4112.
31. Girling R, Partridge JF, Bandara LR, et al . A new component of the transcription factor DRTF1/E2F. Nature 1993; 362: 83-87. (Pubitemid 23087297)
32. Johnson DG, Cress WD, Jakoi L, et al . Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci USA 1994; 91: 12823-12827.
33. Jooss K, Lam EW, Bybee A, et al . Proto-oncogenic properties of the DP family of proteins. Oncogene 1995; 10: 1529-1536.
34. Helin K, Wu CL, Fattaey AR, et al . Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative transactivation. Genes Dev 1993; 7: 1850-1861.
35. Singh P, Wong SH, Hong W. Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J 1994; 14: 3329-3338. (Pubitemid 24226948)